News

As part of the global development and commercialization collaboration, AstraZeneca and Daiichi Sankyo will develop and commercialize trastuzumab deruxtecan (DS-8201), which is an antibody-drug conjugate (ADC) and potential

This is the first time that the FDA has approved a treatment for nr-axSpA. “Today’s approval of Cimzia fulfills an unmet need for patients suffering from non-radiographic axial

The investment will cover a new building dedicated to Merck biotech medicines destined for more than 150 countries, helping to meet increasing patient needs for flagship medicines such

Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals, said: “This approval of Forxiga in Japan means that people with type-1 diabetes whose

SLN124 is being developed for the treatment of iron overload disorders like ß -Thalassemia, Myelodysplastic syndrome (MDS) and Hereditary Hemochromatosis (HH). The investigational candidate was demonstrated to reduce

The multimillion-pound drug discovery alliance will bring together Cancer Research UK’s network of scientists and drug discovery expertise, LifeArc’s therapeutic antibody engineering and development expertise and Ono’s expertise

These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti‐microbial resistance (AMR). MedPharm is a world

Mayzent is claimed to the first oral drug to treat secondary progressive MS with active disease. Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS),

This approval marks the first country approval in the world for SKYRIZI. “With this first global approval of SKYRIZI, we are excited to bring a new treatment option